Who
Caryn Peterson
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Gossamer Bio.
In numbers
- Trades disclosed
- 80
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $152K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Apr 2021
- Last trade
- 24 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —506,250 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —22,784 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —9,167 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —32,334 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —506,250 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —440,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —157,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —157,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —126,667 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —440,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —21,167 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,834 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,784 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,167 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —32,334 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —375,000 | filing |
News
Chardan Capital Begins Coverage on Gossamer Bio (NASDAQ:GOSS)GOSS · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Caryn Peterson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.